Edwards Hedges Bets Between Percutaneous And Surgical Heart Valves
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences will continue developing new surgical heart valves, in addition to potentially more lucrative percutaneous valve technologies
You may also be interested in...
Edwards Plans Percutaneous Valve Trials For European, U.S. Market Approval
Edwards Lifesciences' percutaneous aortic valve PMA submission likely will include a randomized trial with 12-month follow-up
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.